 44 AM / in 7 minutes BRIEF-BeiGene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab Reuters Staff 1 Min Read 
Jan 31 (Reuters) - BeiGene Ltd: 
* BEIGENE INITIATES GLOBAL PHASE 3 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage: